These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 38268496)

  • 1. Effect of lanadelumab on attack frequency and QoL in Japanese patients with hereditary angioedema: Report of five cases.
    Hioki C; Oda Y; Moriwaki S; Fukunaga A
    J Dermatol; 2024 Jun; 51(6):873-877. PubMed ID: 38268496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interventions for the long-term prevention of hereditary angioedema attacks.
    Beard N; Frese M; Smertina E; Mere P; Katelaris C; Mills K
    Cochrane Database Syst Rev; 2022 Nov; 11(11):CD013403. PubMed ID: 36326435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Retrospective Analysis of Long-Term Prophylaxis with Berotralstat in Patients with Hereditary Angioedema and Acquired C1-Inhibitor Deficiency-Real-World Data.
    Johnson F; Stenzl A; Hofauer B; Heppt H; Ebert EV; Wollenberg B; Lochbaum R; Hahn J; Greve J; Trainotti S
    Clin Rev Allergy Immunol; 2023 Dec; 65(3):354-364. PubMed ID: 37914894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of lanadelumab in Japanese patients with hereditary angioedema: A phase 3 multicenter, open-label study.
    Hide M; Ohsawa I; Nurse C; Yu M;
    J Dermatol; 2023 Nov; 50(11):1381-1391. PubMed ID: 37574953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Indirect Comparison of Lanadelumab and Intravenous C1-INH Using Data from the HELP and CHANGE Studies: Bayesian and Frequentist Analyses.
    Mendivil J; Malmenäs M; Haeussler K; Hunger M; Jain G; Devercelli G
    Drugs R D; 2021 Mar; 21(1):113-121. PubMed ID: 33646565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term prevention of hereditary angioedema attacks with lanadelumab: The HELP OLE Study.
    Banerji A; Bernstein JA; Johnston DT; Lumry WR; Magerl M; Maurer M; Martinez-Saguer I; Zanichelli A; Hao J; Inhaber N; Yu M; Riedl MA;
    Allergy; 2022 Mar; 77(3):979-990. PubMed ID: 34287942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-level indirect treatment comparison of lanadelumab versus pdC1-INH i.v. in hereditary angioedema patients: PATCH study.
    Magerl M; Schiffhorst G; Fanter L; Müller G; Hirche C; Berkemeier F; Aygören E
    Allergy; 2024 Jan; 79(1):215-224. PubMed ID: 37641968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The real life experience goes on: update after 4 years on the first cohort treated with lanadelumab at our center.
    Buttgereit T; Vera Ayala C; Aykanat S; Weller K; Gutsche A; Maurer M; Magerl M
    Front Immunol; 2024; 15():1405317. PubMed ID: 38799421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing the cost and quality-of-life impact of on-demand-only medications for adults with hereditary angioedema.
    Castaldo AJ; Jervelund C; Corcoran D; Boysen HB; Christiansen SC; Zuraw BL
    Allergy Asthma Proc; 2021 Mar; 42(2):108-117. PubMed ID: 33581742
    [No Abstract]   [Full Text] [Related]  

  • 10. Lanadelumab in a kidney transplant patient with hereditary angioedema due to C1-inhibitor deficiency and high cardiovascular risk - a case report.
    Gidaro A; La Cava L; Donadoni M; Popescu Janu V; Cogliati C; Brucato AL; Zanichelli A; Cancian M; Bizzi E
    Front Immunol; 2024; 15():1472390. PubMed ID: 39399485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Healthcare utilization of patients with hereditary angioedema treated with lanadelumab and subcutaneous C1-inhibitor concentrate.
    Riedl MA; Hinds DR; Prince PM; Alvord TM; Dosenovic S; Abdelhadi JF; Brownrigg JR; Camp CL; Machnig T; Banerji A
    Allergy Asthma Proc; 2023 Jul; 44(4):275-282. PubMed ID: 37328263
    [No Abstract]   [Full Text] [Related]  

  • 12. Prospective Analysis in Patients With HAE Under Prophylaxis With Lanadelumab: A Real-life Experience.
    Hahn J; Trainotti S; Wigand MC; Schuler PJ; Hoffmann TK; Greve J
    J Drugs Dermatol; 2020 Oct; 19(10):978-983. PubMed ID: 33026762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lanadelumab for the prevention of attacks in hereditary angioedema.
    Valerieva A; Senter R; Wu MA; Zanichelli A; Cicardi M
    Expert Rev Clin Immunol; 2019 Dec; 15(12):1239-1248. PubMed ID: 31721602
    [No Abstract]   [Full Text] [Related]  

  • 14. Lanadelumab to treat hereditary angioedema.
    Wedi B
    Drugs Today (Barc); 2019 Jul; 55(7):439-448. PubMed ID: 31347612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lanadelumab for the Prophylactic Treatment of Hereditary Angioedema with C1 Inhibitor Deficiency: A Review of Preclinical and Phase I Studies.
    Busse PJ; Farkas H; Banerji A; Lumry WR; Longhurst HJ; Sexton DJ; Riedl MA
    BioDrugs; 2019 Feb; 33(1):33-43. PubMed ID: 30539362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An international survey assessing the effects of the duration of attack-free period on health-related quality of life for patients with hereditary angioedema.
    Itzler R; Lumry WR; Sears J; Braverman J; Li Y; Brennan CJ; Koch GG
    Orphanet J Rare Dis; 2024 Jun; 19(1):241. PubMed ID: 38909246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lanadelumab Injection Treatment For The Prevention Of Hereditary Angioedema (HAE): Design, Development And Place In Therapy.
    Bova M; Valerieva A; Wu MA; Senter R; Perego F
    Drug Des Devel Ther; 2019; 13():3635-3646. PubMed ID: 31695331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study.
    Lumry WR; Zuraw B; Cicardi M; Craig T; Anderson J; Banerji A; Bernstein JA; Caballero T; Farkas H; Gower RG; Keith PK; Levy DS; Li HH; Magerl M; Manning M; Riedl MA; Lawo JP; Prusty S; Machnig T; Longhurst H;
    Orphanet J Rare Dis; 2021 Feb; 16(1):86. PubMed ID: 33588897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lanadelumab Efficacy, Safety, and Injection Interval Extension in HAE: A Real-Life Study.
    Buttgereit T; Vera C; Weller K; Gutsche A; Grekowitz EM; Aykanat S; Wahn V; Krüger R; Maurer M; Magerl M
    J Allergy Clin Immunol Pract; 2021 Oct; 9(10):3744-3751. PubMed ID: 34023564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [EFFICACY, PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF INTRAVENOUS C1 INHIBITOR FOR LONG-TERM PROPHYLAXIS AND TREATMENT OF BREAKTHROUGH ATTACKS IN JAPANESE SUBJECTS WITH HEREDITARY ANGIOEDEMA: A PHASE 3 OPEN-LABEL STUDY].
    Fukunaga A; Morita E; Miyagi T; Eto K; Shimizu A; Kagami S; Yamamoto H; Vardi M; Tang Y; Wang Y; Hide M
    Arerugi; 2020; 69(3):192-203. PubMed ID: 32435020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.